Survival and prognostic factors for hepatocellular carcinoma: An Egyptian multidisciplinary clinic experience

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 9, 2014, Pages 3915-3920

  Abdelaziz, Ashraf Omar ^a   Elbaz, Tamer Mahmoud ^a   Shousha, Hend Ibrahim ^a   Ibrahim, Mostafa Mohamed ^a   El Shazli, Mostafa Abdel Rahman ^a   Abdelmaksoud, Ahmed Hosni ^a   Aziz, Omar Abdel ^a   Zaki, Hisham Atef ^a   Elattar, Inas Anwar ^a   Nabeel, Mohamed Mahmoud ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Hepatocellular carcinoma; Multidisciplinary; Prognosis; Survival

Indexed keywords

BILIRUBIN;

BLOOD; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION; COMPLICATION; EGYPT; FEMALE; HUMAN; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; RETROSPECTIVE STUDY; SCHISTOSOMIASIS; TREATMENT OUTCOME;

BILIRUBIN; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; EGYPT; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SCHISTOSOMIASIS; TREATMENT OUTCOME;

EID: 84902679117     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.9.3915     Document Type: Article

References (34)

1. Abdel-Hamid NM, Nazmy MH, Mahmoud AW, Fawzy MA, Youssof M (2011). A survey on herbal management of hepatocellular carcinoma. World J Hepatol. 3, 175-83.
2. Bruix J, Sherman M (2005). Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology, 42, 1208-36.
3. Bruix J, Sherman M (2011). American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology, 53, 1020-2.
4. Bruix J, Sherman M, Llovet JM (2001). EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol, 35, 421-30.
5. Della Corte C, Colombo M (2012). Surveillance for hepatocellular carcinoma. Semin Oncol, 39, 384-98.
6. Dogan E, Yalcin S, Koca D, Olmez A (2012). Clinicopathological characteristics of hepatocellular carcinoma in Turkey. Asian Pac J Cancer Prev, 13, 2985-90.
7. Egyptian Ministry of Health. Egyptian Ministry of Health Annual Report (2007). Available from: http://www.mohp.gov.eg/Main.asp
8. Elbaz T, Kassas M, Esmat G (2013). Management of Hepatocellular Carcinoma: Updated Review. J Cancer Therapy, 4, 536-45.
9. El-Serag HB, Siegel AB, Davila JA, et al (2006). Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol, 44, 158-66.
10. Esmat G, Elbaz T, Kassas M (2013). Hepatocellular carcinoma in Egypt: An updated status. Liver Cancer: Act today, save your life tomorrow. World Gastroenterology Organisation (WGO). WDHD 2013 Final Publication. www.wgofoundation.org/WDHD-2013-Final-Publication.pdf
11. Ezzat S, Abdel-Hamid M, Eissa SA, et al (2005). Associations of pesticides, HCV, HBV, and hepatocellular carcinoma in Egypt. Int J Hyg Environ Health, 208, 329-39.
12. Forner A, Llovet JM, Bruix J (2012). Hepatocellular carcinoma. Lancet, 379, 1245-55.
13. Freedman LS, Edwards BK, Ries LAG (2006). Cancer incidence in four member countries (Cyprus, Egypt, Israel, and Jordan) of the middle east cancer consortium (MECC) compared with US SEER. Bethesda: National Cancer Institute; Available in: http://seer.cancer.gov/publications/mecc/mecc_monograph.pdf
14. Grieco A, Pompili M, Caminiti G, et al (2005). Prognostic factors for survival in patients with earlyintermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut, 54, 411-8.
15. Guy J, Kelley RK, Roberts J, Kerlan R, Yao F, Terrault N (2012). Multidisciplinary management of hepatocellular carcinoma. Clin Gastroenterol Hepatol, 10, 354-62.
16. Kaseb AO, Abaza YM, Roses RE (2013). Multidisciplinary management of hepatocellular carcinoma. Recent Results Cancer Res, 190, 247-59.
17. Khattab MA, Eslam M, Sharwae MA, Hamdy L (2010). Seroprevalence of hepatitis C and B among blood donors in Egypt: Minya Governorate, 2000-2008. Am J Infect Control, 38, 640-1.
18. Kirchner G, Kirovski G, Hebestreit A, et al (2010). Epidemiology and survival of patients with hepatocellular carcinoma in Southern Germany. Int J Clin Exp Med, 3, 169-79.
19. Lee SS, Shin HS, Kim HJ, et al (2012). Analysis of prognostic factors and 5-year survival rate in patients with hepatocellular carcinoma: a single-center experience. Korean J Hepatol, 18, 48-55.
20. Lerose R, Molinari R, Rocchi E, Manenti F, Villa E (2001). Prognostic features and survival of hepatocellular carcinoma in Italy: impact of stage of disease. Eur J Cancer, 37, 239-45.
21. Llovet JM, Bru C, Bruix J (1999). Prognosis of hepatocellular carcinoma:the BCLC staging classification. Semin Liver Dis, 19, 329-38.
22. Llovet JM, Bustamante J, Castells A, et al (1999). Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology, 29, 62-7.
23. National Cancer Registry of Egypt (2010). Magnitude of hepatocellular carcinoma in Egypt. Available from: http://www.nci.cu.edu.eg/
24. Norsa'adah B, Nurhazalini-Zayani CG (2013). Epidemiology and survival of hepatocellular carcinoma in north-east Peninsular Malaysia. Asian Pac J Cancer Prev, 14, 6955-9.
25. Op den Winkel M, Nagel D, Sappl J, et al (2012). Prognosis of patients with hepatocellular carcinoma. Validation and ranking of established staging-systems in a large western HCC-cohort. PLoS One, 7, 45066.
26. Park JW (2002). National policy of early detection in hepatocellular carcinoma. Korean J Hepatol, 8, 16-9.
27. Raza SA, Clifford GM, Franceschi S (2007). Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: a systematic review. Br J Cancer, 96, 1127-34.
28. Takayasu K, Arii S, Ikai I, et al (2006). Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology, 131, 461-9.
29. Tandon P, Garcia-Tsao G (2009). Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int, 29, 502-10.
30. The Egyptian Guidelines for Management of Hepatocellular Carcinoma by Egyptian Society of Liver Cancer. First edition (2011). In: www.egslc.com/content/Guidlines.pdf
31. World Health Organization (2010). Mortality database. IARC. Available from: http://www-dep.iarc.fr/WHOdb/WHOdb.htm
32. Yeh C, Chen M, Lee W, Jeng L (2002). Prognostic factors of hepatic resection for hepatocellular carcinoma with cirrhosis: univariate and multivariate analysis. J Surg Oncol, 81, 195-02.
33. Xu J, Liu C, Zhou L, et al (2012). Distinctions between clinicopathological factors and prognosis of alpha-fetoprotein negative and positive hepatocelluar carcinoma patients. Asian Pac J Cancer Prev, 13, 559-62.
34. Zekri AR, Hassan ZK, Bahnassy AA, et al (2012). Molecular prognostic profile of Egyptian HCC cases infected with hepatitis C virus. Asian Pac J Cancer Prev, 3, 5433-8.